AI
TELO icon

Atom Investors’s Telomir Pharmaceuticals TELO Stock Holding History

Atom Investors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,663
Closed -$47.4K – 803
2025
Q1 		$47.4K Sell
14,663
-354
-2% -$1.55K 0.01% 470
2024
Q4 		$61.9K Buy
+15,017
New +$70.8K 0.01% 464

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Atom Investors's TELO Position: Q2 2025 in Review

Atom Investors sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 14,663 shares — an estimated $47.4K sold.

Atom Investors first reported a position in TELO in Q4 2024 and held it in 2 quarters. The position peaked at $61.9K in Q4 2024. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

  • Atom Investors reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Atom Investors sold 14,663 Telomir Pharmaceuticals shares in Q2 2025, an estimated $47.4K.
  • Atom Investors first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Atom Investors's Telomir Pharmaceuticals position peaked at $61.9K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on Atom Investors's 13F filing for Q2 2025, filed 14 Aug 2025.